Lydie Lemonnier

Lydie Lemonnier

Auto-generated profile, based on publicly available information

Lydie Lemonnier

Association Vaincre la Mucoviscidose, Paris, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
YKYllka Kodra
Yllka Kodra
JWJérôme Weinbach
Jérôme Weinbach
MPManuel Posada de La Paz
Manuel Posada de La Paz
ACAlessio Coi
Alessio Coi
SLS. Lydie Lemonnier
S. Lydie Lemonnier
DTDomenica Taruscio
Domenica Taruscio
Rare diseases (RD) patient registries are powerful instruments that help develop clinical research, facilitate the planning of appropriate clinical trials, improve patient care, and support healthcare management. They constitute a key information system that supports the activities of European Reference Networks (ERNs) on rare diseases. A rapid proliferation of RD registries has occurred during the last years and there is a need to develop guidance for the minimum requirements, recommendations and standards necessary to maintain a high-quality registry. In response to these heterogeneities, in the framework of RD-Connect, a European platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research, we report on a list of recommendations, developed by a group of experts, including members of patient organizations, to be used as a framework for improving the quality of RD registries. This list includes aspects of governance, Findable, Accessible, Interoperable and Reusable (FAIR) data and information, infrastructure, documentation, training, and quality audit. The list is intended to be used by established as well as new RD registries. Further work includes the development of a toolkit to enable continuous assessment and improvement of their organizational and data quality.

1 March 2016 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
CMClémence Martin
Clémence Martin
CHCécile Hamard
Cécile Hamard
RKReem Kanaan
Reem Kanaan
VBVéronique Boussaud
Véronique Boussaud
DGDominique Grenet
Dominique Grenet
PNEUMOLOGIE BurgelPNEUMOLOGIE Burgel
PNEUMOLOGIE Burgel

10 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HCHarriet Corvol
Harriet Corvol
SMSandra de Miranda
Sandra de Miranda
LLLydie Lemonnier
Lydie Lemonnier
AKAstrid Kemgang
Astrid Kemgang
MGMartine Reynaud Gaubert
Martine Reynaud Gaubert
PNEUMOLOGIE BurgelPNEUMOLOGIE Burgel
PNEUMOLOGIE Burgel
Viral infections are known to lead to serious respiratory complications in cystic fibrosis (CF) patients. Hypothesizing that CF patients were a population at high risk for severe respiratory complications from SARS-CoV-2 infection, we conducted a national study to describe the clinical expression of COVID-19 in French CF patients. This prospective observational study involves all 47 French CF centers caring for approximately 7500 CF patients. Between March 1st and June 30th 2020, 31 patients were diagnosed with COVID-19: 19 had positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs; 1 had negative RT-PCR but typical COVID-19 signs on a CT scan; and 11 had positive SARS-CoV-2 serology. Fifteen were males, median (range) age was 31 (9–60) years, and 12 patients were living with a lung transplant. The majority of the patients had CF-related diabetes (n = 19, 61.3%), and a mild lung disease (n = 19, 65%, with percent-predicted forced expiratory volume in 1 s (ppFEV1) > 70). Three (10%) patients remained asymptomatic. For the 28 (90%) patients who displayed symptoms, most common symptoms at admission were fever (n = 22, 78.6%), fatigue (n = 14, 50%), and increased cough (n = 14, 50%). Nineteen were hospitalized (including 11 out of the 12 post-lung transplant patients), seven required oxygen therapy, and four (3 post-lung transplant patients) were admitted to an Intensive Care Unit (ICU). Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further research should establish whether they were not infected or remained asymptomatic upon infection. In diagnosed cases, the short-term evolution was favorable with rare acute respiratory distress syndrome and no death. Post-lung transplant patients had more severe outcomes and should be monitored more closely.

1 January 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
IDIsabelle Durieu
Isabelle Durieu
FDFaustine Dalon
Faustine Dalon
QRQuitterie Reynaud
Quitterie Reynaud
LLLydie Lemonnier
Lydie Lemonnier
CDClémence Dehillotte
Clémence Dehillotte
MBManon Belhassen
Manon Belhassen

23 December 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ABA. Bergougnoux
A. Bergougnoux
ABarnaud billet
arnaud billet
CKC. Ka
C. Ka
MHM. Heller
M. Heller
FDF. Degrugillier
F. Degrugillier
CRC. Raynal
C. Raynal

1 June 2016 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
PDF file
CBC. Bareil
C. Bareil
LLL. Lemonnier
L. Lemonnier
CDC. Dehillotte
C. Dehillotte
VCV. Colomb-Jung
V. Colomb-Jung
CTC. Thèze
C. Thèze
MCM. Claustres
M. Claustres
In 2013 the French CF Registry and CFTR-France database managers started collaborating to address the limitations of each base, due to the lack of genetics and clinical data cross comparison. The aim was to check and update clinical data in CFTR-France and genetic data in the Registry. Records from the two databases were compared using name, date of birth, gender, sex and mutations. Matched and unmatched records were identified. Discrepancies were checked and confirmed by the laboratories and then sent to the CF centres. Comparison of 8807 patients in the Registry and 4617 in CFTR-France identified 1924 full match and 321 partially matched records. Molecular laboratories confirmations added 216 full matches. The remaining 105 patients still need confirmation by laboratories and CF centres. Among the 321 patients, personal data and/or genotype discrepancies were identified for respectively 70 and 129 patients. This database crossing allowed 110 genotypes to be corrected/completed in the Registry, which is of major interest. Indeed, if those incorrect data are also present in the CF centre medical files, they can impact familial genetic counselling and impair patients' access to optimal mutation targeted therapies. Clinical data provided by the Registry are currently being analysed to complete the CFTR-France phenotypic status of patients. In-depth analysis of these data allows patients to be reclassified in different phenotypic groups (CF, CBAVD, isolated bronchiectasis or pancreatitis) and genotype/phenotype relationships to be refined, in order to better manage rare variants interpretation, medical care strategy and genetic counselling to families.